Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasbir Seehra

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Protein Expression and Purification|December 31, 2005
High-throughput identification of refolding conditions for LXRbeta without a functional assayLaura Lin, Jasbir Seehra, Mark L Stahl
FEBS Letters|March 27, 2004
N-linked glycosylation of platelet P2Y12 ADP receptor is essential for signal transduction but not for ligand binding or cell surface expressionXiaotian Zhong, Ron Kriz, Jasbir Seehra, et al.
Science (New York, N.Y.)|July 12, 2003
Crystal structure of the GpIbalpha-thrombin complex essential for platelet aggregationJohn J Dumas, Ravindra Kumar, Jasbir Seehra, et al.
Blood Advances|October 22, 2024
Elritercept, a modified activin receptor IIA ligand trap, increased erythropoiesis and thrombopoiesis in a phase 1 trialJennifer Lachey, Christopher Rovaldi, Suresh Bobba, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|October 30, 2009
Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunctionEmidio E Pistilli, Sasha Bogdanovich, Matias Mosqueira, et al.
The American Journal of Pathology|March 2, 2011
Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophyEmidio E Pistilli, Sasha Bogdanovich, Marcus D Goncalves, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 4, 2008
Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal womenJon Ruckle, Mark Jacobs, William Kramer, et al.
The Journal of Experimental Medicine|January 13, 2010
Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesisSara I Cunha, Evangelia Pardali, Midory Thorikay, et al.
The Journal of Biological Chemistry|June 22, 2012
Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complexSharon A Townson, Erik Martinez-Hackert, Chloe Greppi, et al.
The Journal of Biological Chemistry|July 9, 2011
Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growthRoselyne Castonguay, Eric D Werner, Robert G Matthews, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Protein Expression and Purification|December 31, 2005
High-throughput identification of refolding conditions for LXRbeta without a functional assayLaura Lin, Jasbir Seehra, Mark L Stahl
FEBS Letters|March 27, 2004
N-linked glycosylation of platelet P2Y12 ADP receptor is essential for signal transduction but not for ligand binding or cell surface expressionXiaotian Zhong, Ron Kriz, Jasbir Seehra, et al.
Science (New York, N.Y.)|July 12, 2003
Crystal structure of the GpIbalpha-thrombin complex essential for platelet aggregationJohn J Dumas, Ravindra Kumar, Jasbir Seehra, et al.
Blood Advances|October 22, 2024
Elritercept, a modified activin receptor IIA ligand trap, increased erythropoiesis and thrombopoiesis in a phase 1 trialJennifer Lachey, Christopher Rovaldi, Suresh Bobba, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|October 30, 2009
Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunctionEmidio E Pistilli, Sasha Bogdanovich, Matias Mosqueira, et al.
The American Journal of Pathology|March 2, 2011
Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophyEmidio E Pistilli, Sasha Bogdanovich, Marcus D Goncalves, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 4, 2008
Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal womenJon Ruckle, Mark Jacobs, William Kramer, et al.
The Journal of Experimental Medicine|January 13, 2010
Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesisSara I Cunha, Evangelia Pardali, Midory Thorikay, et al.
The Journal of Biological Chemistry|June 22, 2012
Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complexSharon A Townson, Erik Martinez-Hackert, Chloe Greppi, et al.
The Journal of Biological Chemistry|July 9, 2011
Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growthRoselyne Castonguay, Eric D Werner, Robert G Matthews, et al.
Pageof 3